EU Framework Programme 7 University of Bristol 4
EU Framework Programme 7 University of Bristol 4 th May 2011 Victoria Brewer UK National Contact Point – Health Theme (Academia) International Strategy Manager, Medical Research Council
Agenda • MRC’s role within FP 7 • Funding opportunities within FP 7 • 2012 Health Work Programme • Key points • Topics by activity area
MRC and FP 7 MRC has four roles in FP 7: 1. Participant 2. NCP for the Health Theme – Victoria Brewer • MRC leads the PMC Management delegation at the invitation of 3. Programme the Department of Business Innovation Committee (Health) – Markand Skills (BIS) Palmer • Alternative delegates are: of Health (DH) for 4. • Department State Representative Innovative Medicines • Technology Strategy Board Initiative – Jill Jones • Expert group e. g. UKRO • Joint lead between MRC and BIS
What is FP 7 • Main mechanism used by the European Commission to fund research across Europe. • Two main aims: 1. To strengthen the scientific and technological base of European industry. 2. To encourage international competitiveness while promoting research that supports EU policies. • How does the EC aim to achieve this? • Addressing Pan-European challenges • Pooling resources • Assembling critical mass • Orphan research • Supporting research careers and • Coordinating national and regional • Integration of research • Enabling “big science” mobility of research programmes • Excellence in research • Leverage investment • Creating world private class centres of • Conducting comparative research at • Addressing Specific Needs excellence EU level • EU level competition to increase • Disseminating research result more quality and creativity widely
FP 7 Budget • Seven year funding programme with a budget of around € 50. 5 Billion To date the UK has received 14% of the overall funding awarded
Ideas – European Research Council • € 7. 5 bn budget • Managed through the European Research Council (ERC) • Bottom up/investigator led research • Research within your own team – no international collaboration ERC Advanced Early grants Grants • Funding: ~ € 2. 5 1. 5 M for up to 5 year • “exceptional” 2 -12 years post research Ph. D at application leader • UK has received 172* 180* grants to date • ERC-2010 -Ad. G ERC-2010 -St. G call -79/427 - 53/266 wenttoto. UK UKHEI (19%) (20%)
People – Marie Curie Actions • € 4. 75 bn budget • Managed through Marie Curie Actions • Research mobility and career development scheme –inc’ coordination of Ph. D programmes • Allows for European and International exchange • Schemes for individuals or organisations Organisation Individual • • € 1. 3 Initial Mariebillion Curie Training Intra-European Networks (ITNs) Fellowships – aimed for at initial Career training • To date awarded of Development researchers, first (IEF) five -move yearsfrom of researchers' one EU or FP 7 careers. associated Projects • UK share € 300. 8 million = 23% will country be based to another aroundfor a Joint a duration Training of 1 -2 Programme years. focussing on • scientific Marie Curie and technological International knowledge, Incomingas Fellowships well as other(IIF) – complementary bring researchers skills based such outside as IPR, Europe research intomanagement, an EU Member entrepreneurship State or country associated to FP 7 for a duration of 1 -2 years. • Co-funding of Regional, National and International Programmes (COFUND) - encourage existing or new regional or national programmes to open up and provide for trans-national mobility, as well as to reinforce international programmes.
Cooperation • € 32. 4 bn budget • Top-down research • EC sets the Research Agenda • Proposals must be topic specific • Multiple-disciplinary • Collaborative research • MUST be working with European Partners (or Associated Countries/ target specific countries) • 3 is a magic number • SICA – 2 x MS/AC & 2 x target region(s)
Who is eligible to participate? • EU-27 – Member States (MS) Austria, Belgium, Bulgaria , Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Ireland, Latvia, Lithuania, Luxemburg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, UK • Associated Countries (AC) Albania*, Bosnia and Herzegovina *, Croatia*, Faroe Islands*, FYR, Macedonia*, Iceland*, Israel*, Liechtenstein*, Montenegro*, Norway*, Serbia*, Switzerland, Turkey* *except Euratom
Third countries: ICPC
What organisation can participate? • Participation is open to a wide range of organisations and individuals: • • research groups at universities or research institutes small or medium-sized enterprises (SMEs) SME associations or groupings public or governmental administration (local, regional or national) • organisations and researchers from third countries • international organisations • civil society organisations • Need to register your organisation with the EC
Cooperation Health Food, Agriculture, Fisheries, Biotechnology Information and Communication Technologies Nano-sciences, nano-technologies, materials and new production technologies Energy Environment € 6. 1 bn Obesity, allergies, € 1. 9 bn zoonoses and systems Medication biology € 9. 1 bninformation technologies, activities on ageing, patient safety and virtual physiological human Biomaterials for health € 3. 5 bn being application, nanomedicines and nanotoxicology € 2. 4 bn Environment € 1. 9 bn and Health Transport € 4. 2 bn Socio-economic sciences and the humanities € 0. 6 bn Space € 1. 4 bn Security € 1. 4 bn
2012 Health Work Programme Research priorities 1. 2. 3. 4. Active & Healthy Ageing • Europe 2020 - Innovation Union The pilot European Innovation Partnership on active and healthy ageing • 5 topics each looking to fund more than 1 proposal, 4 x € 6 m and 1 x € 12 m Medical technologies • Supporting the “innovation" strategy and reduce the time to market • 7 topics each looking to fund more than 1 proposal, 6 x € 6 m and 1 x € 3 m Rare diseases • Build critical mass for research on rare diseases • Currently 4 topics and 1 HIP but likely to become 7 topics Clinical Trials • Continue on initiative started in 2011 work programme • Improve the quality of clinical trial data in Europe • 1 x Active and Healthy ageing, 2 x Rare diseases and 1 x. Diabetes (type 1)
2012 Health Work Programme Key features to look out for. . • Strong SME focus in the majority of call topics: • SME-targeted ≥ 30% budget • SME-focus ≥ 15% budget • Majority of call are 2 stage (exceptions CSA and ERA Net) Process 2011 WP Deadline • Outline submission 13 th Oct 2010 • Invitation to second stage ~ 20 th Dec 2010 • Full proposal submission 10 th Feb 2011 • Results ~ end April/early May 2011
2012 Health Work Programme CLOSED AREAS: 1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH • 1. 1 High-throughput research • 1. 3 Suitability, safety, efficacy of therapies 2. TRANSLATING RESEARCH FOR HUMAN HEALTH DRAFT • 2. 2. 1 Brain and brain-related diseases • 2. 3. 1 Anti-microbial drug resistance Refer to the final • 2. 3. 3 Potentially new and re-emerging epidemics published • 2. 3. 4 Neglected infectious diseases version • 2. 4. 1 Cancer when released • 2. 4. 2 Cardiovascular diseases 3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS • 3. 1 Translating the results of clinical research outcome into clinical practice including better use of medicines, and appropriate use of behavioural and organisational interventions and new health therapies and technologies • 3. 3 Health promotion and prevention 4. OTHER ACTIONS ACROSS THE HEALTHTHEME • 4. 2 Responding to EU policy needs
The Health Theme 1 Biotechnology, generic tools and medical technologies for human health 2 3 Translating research for human health Optimising the delivery of healthcare to European citizens 4 Emerging policy needs/unforeseen needs
1. 2 DETECTION, DIAGNOSIS AND MONITORING • HEALTH. 2012. 1. 2 -1. Development of technologies with a view to patient group stratification for personalised medicine applications. Key points: • SME-targeted Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call ≥ 30 % Focus: • Research and development of technologies application of tailored medical intervention in specifically defined patient group • Proof of principle highlighted • Emphasis of data collection and analysis i. e. statistical tool + quality control around this • Active inclusion of end users (particular for proof of principle)
1. 3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES Innovative Medicines Initiative • • Joint EC and EFPIA funding scheme = € 2 billion Research areas in • Safety • Efficacy • Education & training • Knowledge management • 4 th call Estimated launched in June 2011 • Indicative topics: – Assessment of drug-induced toxicity in relevant organs – surrogates for early drug failure – Enhancing translation in neurological diseases – European Medical Information Systems – Stem Cells for drug development and toxicity screening – Beyond high-throughput screening – Disease heterogeneity/taxonomy of disease – Genetic mapping of extreme phenotypes – Combination therapy development
1. 4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS Focus = Transplantation Rationale: • Clinical demand • Continuity of successful FP 6 projects • Recent progress in other areas • Policy developments i. e. DG SANCO
1. 4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS • HEALTH. 2012. 1. 4 -1: Innovative approaches to solid organ transplantation. Key points: • SME-focused Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call ≥ 15 % Focus: • Improve the outcome, increase efficiency &/or widen the scope of solid transplantation • Clinical focus inc’. Regulatory, safety & immunological aspects • Improved treatment improved personal targeting & tolerance
1. 4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS • HEALTH. 2012. 1. 4 -2: Medical technology for the transplantation sector and bioartificial organs Key points: • SME-targeted Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call Focus: • Develop novel tools, techniques & devices for use in transplantation and in bioartifical organs • Include cells, tissues or organs • Clinical/in-patient trial = central to the proposal • Cover safety & efficacy assessment + regulatory work ≥ 30 %
1. 4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS • HEALTH. 2012. 1. 4 -3: Innovative strategies for translation of stem cell based therapies in regenerative medicine. Key points: • SME-targeted Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call • EU and Australia Cooperation • • ≥ 15 % EU & Australian Partners ~ 50% work carried out in Australia Joint submission to EC and NHMRC Australian Partners apply to NHMRC ≠ request EU funds € 6 m max EC contribution to European Team Max NHMRC contribution = € 6 m
1. 4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS • HEALTH. 2012. 1. 4 -2 cont’. Focus: • Characterisation • Mechanisms of action and nature of host response(s) • Quality control of product(s), • Efficacy and safety in relevant preclinical models • • • Bridging studies can be included 2 phase project 2 nd stage dependent on regulatory approval • 5 year – review at Yr 3 Yrs 4&5 dependent on approval of joint regulatory filing • funds divided equally between the 2 phases Outcome = Therapeutic products & clinical protocols developed with industrial partners
1. 4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS • HEALTH. 2012. 1. 4 -4: Targeted nucleic acid delivery as an innovative therapeutic or prophylactic approach. Key points: • SME-targeted Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call ≥ 30 % Focus: • Immunotherapy, gene therapy or DNA vaccination, RNA interference • Clinical testing carried out throughout of the life time of the project – inc’. regulatory work • Preclinical work around safety, immunogenicity, toxicity and feasibility studies should have already been completed
The Health Theme 1 Biotechnology, generic tools and medical technologies for human health 2 3 Translating research for human health Optimising the delivery of healthcare to European citizens 4 Emerging policy needs/unforeseen needs
2. 1 INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY 2. 1. 1 Large-scale data gathering • HEALTH. 2012. 2. 1. 1 -1: Clinical utility of -omics for better diagnosis and treatment of rare diseases. Key points: • WAS a High Impact Project – going to broken down into individual Collaborative Project Focus: • New topics = Still TBC • Likely to cover • -omics approaches and technologies for molecular characterisation for a chosen rare disease new diagnostics and treatment in clinical settings • Utilisation of existing databases/biobanks • Coordination and harmonisation of patient registries
2. 1. 1 Large-scale data gathering (cont’. ) • HEALTH. 2012. 2. 1. 1 -2: Validation of -omics-based biomarkers for diseases affecting the elderly. Key points: • SME-targeted Collaborative Project up to € 12 m • One or more proposals can be selected. • Two-stage call ≥ 30 % Focus: • Clinical validation already identified -omics based biomarkers sensitivity, specificity and predictive power improved diagnosis, prognosis, patient stratification and/or treatment monitoring • Inc’. statistical models and quality control for data generated
2. 1. 1 Large-scale data gathering (cont’. ) • HEALTH. 2012. 2. 1. 1 -3: Statistical methods for collection and analysis of -omics data. Key points: • SME-targeted Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call ≥ 15 % Focus: • Improve or develop new statistical models / tools for analysis of –omic based data • Open to any –omics based data e. g. genomics, proteomics etc or particular class of analysis • Clinical trials excluded • Must include appropriate training and dissemination activities
2. 1 INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY 2. 1. 2 Systems biology • HEALTH. 2012. 2. 1. 2 -1: Systems medicine: SME-driven research applying systems biology approaches to address medical and clinical needs. Key points: • SME-targeted Collaborative Project up to € 3 m • One or more proposals can be selected. • Two-stage call • Small to minimum consortium sizes • Project duration up to 2 years • No intermediate payments or reports ≥ 30 %
2. 1. 2 Systems biology (cont’. ) • HEALTH. 2012. 2. 1. 2 -1 cont’. Focus: • Development, improvement and application of systems biology approaches to medical/clinical questions e. g. : • Re-design of clinical trials by shortening timescale and costs; • Development of combinatorial therapies and/or chronotherapies for complex diseases • Development of combinatorial biomarkers • Etc… • • Establish proof-of-concept demonstrate the potential for exploitation Exploitation of results in clinical an/ or industrial sectors
2. 1. 2 Systems biology (cont’. ) • HEALTH. 2012. 2. 1. 2 -2: Systems medicine: Applying systems biology approaches for understanding complex human diseases and their co-morbidities. Key points: • Collaborative Project up to € 12 m • One or more proposals can be selected. • Two-stage call Focus: • Integrated multidisciplinary research inc’. pre-clinical and clinical research clinicians, biologists computational scientists, mathematician etc • Address a clear clinical need new avenues of understanding patho-physiology, diagnosis and treatment of complex diseases
2. 1. 2 Systems biology (cont’. ) • HEALTH. 2012. 2. 1. 2 -3: Preparing for the future research and innovation activities in systems medicine. Key points: • Coordination and Support Action (CAS) up to € 3 m • Only one proposals can be selected. • Two-stage call Focus: • Promote, support and coordinate research activities in systems biology across Europe • Best practice, information and resources of successful methodological approaches. • Multidisciplinary training requirements for the next generation • Promote innovation activities technology transfer exploitation http: //ec. europa. eu/research/health/past-events_en. html
2. 2 RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING 2. 2. 2 Human development and ageing = Primary focus Rationale: • Europe has highest proportion of older people in the world • Grand challenge of understanding the ageing process • More targeted geriatric medicines • Innovation Union partnership – Active and Healthy Ageing http: //ec. europa. eu/research/innovationunion/index_en. cfm? section=active-healthy-ageing
2. 2. 2 Human development and ageing • HEALTH. 2012. 2 -1: Integrative systems biology and comparative genomics for studying human ageing and/or most common age-related diseases. Key points: • SME-targeted Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call ≥ 30 % Focus: • Interactions between genetics, epigenetic and environmental factors ageing phenotype in normal and disease conditions • Computational approaches, comparative genomic studies of existing data and appropriate modelling • Can include tools for diagnosis, prognosis and monitoring of therapies
2. 2. 2 Human development and ageing (cont’. ) • HEALTH. 2012. 2. -2: Investigator-driven clinical trials for optimisation of management of elderly patients with multiple diseases. Key points: • SME-targeted Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call ≥ 15 % Focus: • Compare various treatment regimens in elderly population treated for multiple diseases • Clinical trials looking at efficacy and adverse effects of multi treatment of common age related diseases
2. 3 TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH 2. 3. 0 Cross-cutting • HEALTH. 2012. 2. 3. 0 -1: Diagnostics for infectious diseases. Key points: • SME-targeted Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call • No prescribed duration i. e. can be as short as 1 -2 years ≥ 30 % Focus: • Development and/or validation of diagnostic tests for major infectious diseases to meet clinical need • Priority to diseases with unmet medical need i. e. no tests available & improved testing better control and management
2. 3 TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH 2. 3. 2 HIV/AIDS, malaria and tuberculosis • HEALTH. 2012. 2. 3. 2 -1: Co-infection of HIV/AIDS, malaria, tuberculosis and/or hepatitis. Key points: • Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call Focus: • Basic, translation and/or clinical research • prevention, therapeutic management and prognosis of coinfected patients • Immunological mechanisms and response to co-infection • Priority to co-morbidity of relevance to LMIC
2. 3. 2 HIV/AIDS, malaria and tuberculosis (cont’. ) • HEALTH. 2012. 2. 3. 2 -2: Co-morbidity between infectious and non-communicable diseases. Key points: • Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call Focus: • Basic, translation and/or clinical research • prevention, therapeutic management and prognosis of patients infectious and non-communicable diseases • Proposals should address: • Causative links between infectious and non-infectious diseases • Combination of 3 major poverty related diseases (AIDS, malaria or TB) or any major poverty related diseases with non-infectious diseases
2. 3. 2 HIV/AIDS, malaria and tuberculosis (cont’. ) • HEALTH. 2012. 2. 3. 2 -3: Prevention and treatment for HIV/AIDS, malaria and tuberculosis. Key points: • SME-targeted collaborative Project up to € 6 m • One or more proposals can be selected. ≥ 15 % • Two-stage call • No prescribed duration i. e. can be as short as 1 -2 years Focus: • Basic or translation research addressing current gaps in • Prevention and/or treatment of poverty related diseases (HIV/AIDS, malaria or TB) • Proposal must inc’: • Detailed plan for exploitation of end results • Explore synergies with relevant EU funded initiatives e. g. European and Developing Countries Clinical Trial Partnership (EDCTP)
2. 3. 2 HIV/AIDS, malaria and tuberculosis (cont’. ) • HEALTH. 2012. 2. 3. 2 -4: Low-cost interventions for disease control in resource poor settings. Key points: • Collaborative Project up to € 3 m • One or more proposals can be selected. • Two-stage call Focus: • Innovative ways to control neglected infectious diseases and/or malaria low-cost interventions – immediate impact • Novel applications of current tools and knowledge new costeffective solutions • • Combinational therapy, treatment strategies, epidemiology, access to diagnostics and drugs, operational and implementation research Inclusion of partners from disease-endemic countries
2. 4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES 2. 4. 3 Diabetes and obesity • HEALTH. 2012. 2. 4. 3 -1: Innovative approach to manage diabetes. Key points: • SME-targeted Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call ≥ 30 % Focus: • Management of diabetes in pre-and/or clinical settings by validating therapeutic devices or biological therapies • Attention to safety, bio-compatibility, interoperability and regulatory aspects fast and safe uptake of approaches/technologies
2. 4. 3 Diabetes and obesity (cont’. ) • HEALTH. 2012. 2. 4. 3 -2: Investigator-driven clinical trials for type 1 diabetes research. Key points: • Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call Focus: • Clinical Trial on type 1 diabetes with focus on paediatric population improve glycolic control and/or reduce diabetes complications • Inform clinical management of type 1 diabetes • Excludes pilot studies and systematic reviews
2. 4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES 2. 4. 4 Rare diseases (= < 5/10, 000) • HEALTH. 2012. 2. 4. 4 -1: Preclinical and/or clinical development of substances with a clear potential as orphan drugs. Key points: • Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call Focus: • MUST be EU designated orphan medicinal products • http: //ec. europa. eu/health/documents/communityregister/html/orphreg. htm • Preclinical studies in models and/or clinical studies • Excludes cancer and diseases of the nervous system ≥ 30 %
2. 4. 4 Rare diseases (cont’. ) • HEALTH. 2012. 2. 4. 4 -2: Observational trials in rare diseases. Key points: • Collaborative Project up to € 3 m • One or more proposals can be selected. • Two-stage call Focus: • Rare diseases with no orphan drug available – treated off-label • Improve clinical management of rare diseases evidence based clinical guidance • Data collection and comparing outcomes of various treatment regimens • • Evaluation of effectiveness and adverse events Excludes cancer, infectious diseases and diseases of the nervous system
2. 4. 4 Rare diseases (cont’. ) • HEALTH. 2012. 2. 4. 4 -3: Best practice and knowledge sharing in the clinical management of rare diseases. Key points: • Coordination and Support Action (CAS) up to € 2 m • Only one proposals can be selected. • Two-stage call Focus: • Development of a networking platform supporting the collection of standardised & validated data and exchange of information providing evidence of best clinical management of rare diseases • Identify additional research needs • Any group of rare diseases
2. 4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES 2. 4. 5 Other chronic diseases • HEALTH. 2012. 2. 4. 5 -1: Technological approaches to combating sensory impairments. Key points: • SME-targeted Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call ≥ 30 % Focus: • Preclinical and clinical testing of novel tools, devices or therapies' for overcoming sensory disability • Prevention and treatment strategies, technological approaches, biological cell based therapies inc’. Stem cells and development of bio-artificial organs
2. 4. 5 Other chronic diseases (cont’. ) • HEALTH. 2012. 2. 4. 5 -2: Biomarkers and diagnostics for chronic inflammatory diseases of the joints and/or digestive system. Key points: • SME-targeted Collaborative Project up to € 6 m • One or more proposals can be selected. • Two-stage call Focus: • Development of improved/novel methodologies early diagnosis of chronic inflammatory diseases • Indicative markers for inflammatory onset and development & evaluation of intervention therapies ≥ 15 %
The Health Theme 1 Biotechnology, generic tools and medical technologies for human health 2 3 Translating research for human health Optimising the delivery of healthcare to European citizens 4 Emerging policy needs/unforeseen needs
3. 2 QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS • HEALTH. 2012. 3. 2 -1: Improving the organisation of health service delivery. Key • • points: Collaborative Project up to € 3 m One or more proposals can be selected. Two-stage call ~ 4 year duration Focus: • Best practice for European health care organisations around, structure, care processes and performance • Areas to be addressed (either one or many): 1. integration of patient care 2. Patient centred care and involvement 3. Skill mix and management of resources (only 1 proposal) 4. Transfer of knowledge into practice ~ span 5 years
3. 2 QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS • Key • • • HEALTH. 2012. 3. 2 -2: New methodologies for health technology assessment. points: Collaborative Project up to € 3 m One or more proposals can be selected. Two-stage call Focus: • Develop new and/or improved methodologies for Health Technology Assessment (HTA) • Areas of focus (either or both): 1. Methodologies for addressing the complexity of interventions 2. Methodologies to assess the efficacy and effectiveness of technologies • Complement previously funded work i. e. EUnet. HTA JA http: //www. eunethta. net/
3. 4 INTERNATIONAL PUBLIC HEALTH & HEALTH SYSTEMS • HEALTH. 2012. 3. 4 -1: Health systems/services research in low and middle income countries. Key • • • points: SICA up to € 6 m 6 x ICPC and min 2 x EU/AC One or more proposals can be selected. Two-stage call ~ 5 years in duration Focus: • Collection, analysis and translation of data into effective health service planning and policy • Focus on (either): 1. Methods to investigate country comparisons and scientific capacity 2. Human resources for health 3. Knowledge transfer • Balanced partnership
The Health Theme 1 Biotechnology, generic tools and medical technologies for human health 2 3 Translating research for human health Optimising the delivery of healthcare to European citizens 4 Emerging policy needs/unforeseen needs
4. 1 COORDINATION AND SUPPORT ACTIONS ACROSS THEME • HEALTH. 2012. 4. 1 -1: Network to encourage knowledge transfer activity in FP-funded health research (especially in academic and governmental organisations). CSA € 2 m • HEALTH. 2012. 4. 1 -2: Training actions linked to intellectual property rights management and knowledge transfer. CSA € 2 m • HEALTH. 2012. 4. 1 -3: Support for Presidency events: Organisation of supporting actions and events related to the Presidency of the European Union. CSA € 100, 000 • HEALTH. 2012. 4. 1 -4: Support for the international rare disease research. CSA € 100, 000 • HEALTH. 2012. 4. 1 -5: Communicating the benefits of European research to the general public. CSA € 100, 000
Contacts • NCP Health (Academia): Victoria Brewer victoria. brewer@headoffice. mrc. ac. uk 020 7395 2205 • NCP Health (Industry): Graham Hughes graham. hughes@betatechnology. co. uk 01302 322633 • NCP ERC & Marie Curie: UK Research Office ukro@bbsrc. ac. uk 00 32 2 230 1535 /5275
Useful websites • EC website: http: //cordis. europa. eu/fp 7/home_en. html • Connect FP 7: https: //ktn. innovateuk. org/web/fp 7 uk • UKRO website: http: //www. ukro. ac. uk/ • MRC website – International funding opportunties: http: //www. mrc. ac. uk/Fundingopportunities/Internationalop portunities/index. htm
Useful websites • Europe 2020 Strategy http: //ec. europa. eu/resource-efficient-europe/ • Innovation Union http: //ec. europa. eu/research/innovationunion/index_en. cfm? pg=intro • Active and Healthy Ageing http: //ec. europa. eu/research/innovationunion/index_en. cfm? section=active-healthy-ageing • EDCTP http: //www. edctp. org/
Any questions?
- Slides: 58